Salta al contenuto principale
Passa alla visualizzazione normale.

VALERIO GRISTINA

Network approach in liquidomics landscape

  • Autori: Santini, Daniele; Botticelli, Andrea; Galvano, Antonio; Iuliani, Michele; Incorvaia, Lorena; Gristina, Valerio; Taffon, Chiara; Foderaro, Simone; Paccagnella, Elisa; Simonetti, Sonia; Fazio, Federico; Scagnoli, Simone; Pomati, Giulia; Pantano, Francesco; Perrone, Giuseppe; De Falco, Elena; Russo, Antonio; Spinelli, Gian Paolo
  • Anno di pubblicazione: 2023
  • Tipologia: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/605553

Abstract

Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer, but it also has many limits to be frequently executed, being too invasive with the risk of side effects. These limits and the ability of cancer to constantly evolve its genomic profile, have recently led to the need of a less invasive and more accurate alternative, such as liquid biopsy. By searching Circulating Tumor Cells and residues of their nucleic acids or other tumor products in body fluids, especially in blood, but also in urine, stools and saliva, liquid biopsy is becoming the future of clinical oncology. Despite the current lack of a standardization for its workflows, that makes it hard to be reproduced, liquid biopsy has already obtained promising results for cancer screening, diagnosis, prognosis, and risk of recurrence.Through a more accessible molecular profiling of tumors, it could become easier to identify biomarkers predictive of response to treatment, such as EGFR mutations in non-small cell lung cancer and KRAS mutations in colorectal cancer, or Microsatellite Instability and Mismatch Repair as predictive markers of pembrolizumab response.By monitoring circulating tumor DNA in longitudinal repeated sampling of blood we could also predict Minimal Residual Disease and the risk of recurrence in already radically resected patients.In this review we will discuss about the current knowledge of limitations and strengths of the different forms of liquid biopsies for its inclusion in normal cancer management, with a brief nod to their newest biomarkers and its future implications.